Ep. 6: Measuring the Impact of Medical Affairs

Measuring the impact of the Medical Affairs (MA) organization is not as straightforward as it is for other functions (e.g., increase in revenue or market share for Commercial) and remains a challenge for most pharmaceutical companies today. There have historically been no simple metrics to evaluate the influence of MA, so our host Peg Crowley-Nowick, PhD, MBA, Founder & President of Zipher Medical Affairs met with Meg Heim, RN, MBA, previously Vice President, Global Head of Scientific Engagement Strategy, Operations and Program Management at Sanofi and currently President at Heim Global Consulting, to discuss a methodology she developed and employed to truly measure the effectiveness of the Medical Affairs (MA) organization.

After briefly touching on Meg’s experience in advocacy and policy and its importance in advancing MA, Dr. Crowley-Nowick asks Meg to explain what MA has to do to demonstrate impact. The conversation focused on how to measure impact over time and ensure that this resonates throughout an organization. Additionally, Meg addresses the importance of working with vendor partners to fill in gaps in expertise and to provide support services that can prove to be incredibly valuable for insights, decision making, and refining strategy (e.g., data on key opinion leaders). This sixth episode of Zipher’s Medical Affairs Unscripted closes with how to use artificial intelligence to analyze insights to avoid bias and advance medical strategy.

The podcast is available from the player in the sidebar, or on the platforms below:

Dr. Zhen Su, MBA, Senior Vice President and Global Head of Oncology, Merck KGaA

Listen to the podcast below:

Looking to learn more about our service offerings?

Call 508.748.3007 today or please fill out the form below.